Piper Sandler analyst Yasmeen Rahimi downgraded Prometheus (RXDX) to Neutral from Overweight with a price target of $200, up from $138, after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
- Prometheus downgraded to Neutral from Buy at Guggenheim
- Merck deal for Prometheus a ‘strategic positive,’ says BofA
- Merck acquisition has potential to be ‘great deal,’ says Citi
- Prometheus downgraded to Hold from Buy at Stifel
- Prometheus downgraded to Neutral from Buy at BTIG
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue